Whiting Nancy 4

What Happened

• Nancy Whiting, a director of Caribou Biosciences, was granted a derivative equity award for 45,000 shares on Feb 20, 2026. The award was issued at $0.00 per share (total reported value $0) and is reported as a derivative grant (not an open-market buy or sale).

Key Details

• Transaction date: 2026-02-20
• Transaction type: Grant / award of a derivative security (45,000 shares) at $0.00 per share
• Total reported cash value on Form 4: $0
• Vesting: One-twelfth of the shares vest on each monthly anniversary of the grant date; fully vested on Feb 20, 2027, subject to continued service (per filing footnote)
• Shares owned after transaction: Not disclosed in this Form 4
• Filing timeliness: Reported for the transaction date (no late filing indicated)

Context

• This was a compensation grant to a director, not a market purchase or sale. Such awards commonly align director incentives with shareholders; they are not a direct sign of buying or selling activity in the open market.
• Because this is a derivative award with a staggered monthly vesting schedule, the recipient must continue service to realize the full award over the next 12 months.